Incorporated in 2009 and based in Jackson Center, Pennsylvania, Halberd Corporation (OTCMKTS:HALB) recently issued a release launching “proof of concept” thereby taking a major leap in the eradication of several transmittable diseases which includes malaria, tuberculosis, sepsis, meningitis to name a few. This is made possible through its laser emissive energy exposure technique which removes the E. Coli bacteria. The patent rights of this technique are however still awaited.
The test was conducted in the supervision of Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at Youngstown State University wherein the bacteria were mixed with a metallic nanoparticle complex, created through Halberd’s patent-pending process, designed to bind with the E. coli cells prior to exposing the mixture to laser energy. Affirming the success of the first time a tuned laser in the elimination of the disease antigens.
Overwhelmed with the success of the same, Mr. Mitchell S. Felder, M.D., the co-inventor of this innovative technology, and the Chief Technology Officer of Halberd Corporation stated, “More than one out of four people on earth are destined to die from an infectious disease. Imagine a world where there is no threat from any infectious disease: no COVID-19, no malaria, no tuberculosis, no sepsis, no meningitis, no pandemics. The successful experimentation we have conducted in collaboration with Youngstown State University (YSU) and Arizona State University (ASU), may serve as the first step to an elegant solution to these worldwide tragedies.”
Further, William A. Hartman, Halberd’s Chairman, President & CEO, stated, “This is a clear breakthrough in the eradication of disease. Our extensive review of medical research reports reveals no other successful use of a nano-laser for pathogen eradication. Over the next few weeks, we will apply what we learned in these E. coli experiments to eliminate from Cerebral Spinal Fluid the disease antigens comprising Alzheimer’s Disease and PTSD.
In parallel, we will be conducting the initial RF exposure disease-elimination experiments, now that we have secured a more powerful RF generator. We expect our RF test results to mirror those displayed during our laser tests. This will be closely followed by proof-of-concept testing of our patent-pending Chemical Bonding Process. Having alternative treatment methods will offer health care professionals the flexibility to select the most suitable approach for each patient, disease condition and environment.”
On Wednesday, HALB stock soared 149% at $0.0511 with more than 194.66 million shares, compared to its average volume of 7.02 million shares.